Latest News

Timely guideline-concordant care may mitigate racial and ethnic disparities in overall survival among patients with inflammatory breast cancer.
Data Show Guideline-Concordant Care Gaps in Inflammatory Breast Cancer

March 20th 2025

Timely guideline-concordant care may mitigate racial and ethnic disparities in overall survival among patients with inflammatory breast cancer.

The safety profile of vepdegestrant in ER–positive/HER2– breast cancer was consistent with its observed profile in previous studies.
Vepdegestrant Meets PFS Primary End Point in ESR1m ER+/HER2– Breast Cancer

March 12th 2025

The Rapid Evolution of Cardiotoxicity in Breast Cancer and Why More Data is Needed
The Rapid Evolution of Cardiotoxicity in Breast Cancer and Why More Data is Needed

March 11th 2025

Sexual Health Considerations to Improve Survivorship in Breast Cancer
Sexual Health Considerations to Improve Survivorship in Breast Cancer

March 11th 2025

The test led to a modification in treatment plan for 48.1% of those with stage I to III HER2-positive breast cancer, 73.5% of which were reductions.
Genomic Assay Yields Strong Predictive Accuracy in HER2+ Breast Cancer

March 11th 2025